Health Canada accepts GSK Jemperli review for dMMR/MSI-H locally advanced rectal cancer
GSK•Health Canada accepted GSK’s Jemperli submission for review in previously untreated stage II-III dMMR/MSI-H locally advanced rectal cancer, backed by phase II AZUR-1 data showing sustained complete responses at 12 months.
1. Review accepted
Health Canada accepted GSK’s Jemperli submission for review through the accelerated NOC/c pathway and Project Orbis collaborative oncology program. The filing is supported by phase II AZUR-1 data showing sustained complete responses at 12 months.
